Erythromycin Drug Interactions: A Comprehensive Review

Chouaia Deeraksa^*
*Correspondence: Chouaia Deeraksa, Department of Medicine, Chiang Mai University, Chiang Mai, Thailand, Email:

Keywords

Erythromycin • Pharmacokinetics • Prokinetic agent • Clinical implications

Introduction

Erythromycin is a macrolide antibiotic derived from the bacterium S.erythraea. It is commonly prescribed to treat a range of bacterial infections, including respiratory tract infections, skin infections, and sexually transmitted diseases. Additionally, erythromycin has prokinetic properties, making it useful in managing gastroparesis. However, its use is often complicated by its potential to interact with a variety of other medications. The primary mechanism of these interactions is erythromycin's inhibition of the cytochrome P450 enzyme system, particularly CYP3A4, a key enzyme in the metabolism of many drugs. This review provides an in-depth analysis of erythromycin's drug interactions, focusing on their mechanisms, clinical significance, and strategies to mitigate adverse effects [1].

Literature Review

Erythromycin exerts its antibacterial effects by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis. Its prokinetic effect is achieved by stimulating motilin receptors in the gastrointestinal tract, enhancing gastric emptying. The drug is available in several formulations, including erythromycin base, stearate, estolate, and ethylsuccinate, each with distinct pharmacokinetic properties. Erythromycin is well-absorbed from the gastrointestinal tract but undergoes extensive first-pass metabolism, resulting in variable bioavailability. It is widely distributed in body tissues and fluids, and it is predominantly metabolized in the liver by the CYP3A4 enzyme, with metabolites excreted in bile and urine [2].

Statins (e.g., simvastatin, atorvastatin) are commonly prescribed for hyperlipidemia. Erythromycin inhibits the metabolism of statins by CYP3A4, leading to elevated plasma concentrations and an increased risk of statin-induced myopathy and rhabdomyolysis. Clinical management includes monitoring for signs of muscle toxicity and considering alternative antibiotics or lipid-lowering therapies. Calcium channel blockers (e.g., verapamil, diltiazem) are metabolized by CYP3A4. Co-administration with erythromycin can result in increased plasma levels of these antihypertensive agents, potentially causing hypotension, bradycardia, and other cardiovascular effects. Dose adjustments and close monitoring are recommended when these drugs are used concurrently. Warfarin, a commonly used anticoagulant, is metabolized by CYP2C9 and CYP3A4. Erythromycin can enhance the anticoagulant effect of warfarin by inhibiting its metabolism, increasing the risk of bleeding. Regular monitoring of the International Normalized Ratio (INR) and adjusting the warfarin dose is essential in such cases [3].

Discussion

Azole antifungals (e.g., ketoconazole, itraconazole) are potent inhibitors of CYP3A4 and can increase erythromycin levels, raising the risk of toxicity. Conversely, erythromycin can increase the levels of azoles by inhibiting their metabolism. This bidirectional interaction necessitates careful dose adjustments and monitoring for adverse effects. Benzodiazepines (e.g., midazolam, triazolam) are metabolized by CYP3A4. Erythromycin can increase the plasma levels of these sedative-hypnotic drugs, leading to excessive sedation and respiratory depression. Alternative antibiotics or benzodiazepines not metabolized by CYP3A4 should be considered. Immunosuppressants such as cyclosporine and tacrolimus are metabolized by CYP3A4. Erythromycin can increase their plasma concentrations, heightening the risk of nephrotoxicity and other adverse effects. Frequent monitoring of drug levels and renal function is advised when these drugs are co-administered with erythromycin [4].

Protease inhibitors (e.g., ritonavir, saquinavir) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) (e.g., efavirenz) used in HIV treatment are metabolized by CYP3A4. Erythromycin can elevate the levels of these antiretroviral agents, potentially leading to increased toxicity. Dose adjustments and therapeutic drug monitoring are critical in managing these interactions. The clinical implications of erythromycin's drug interactions are significant and warrant careful consideration. These interactions can lead to severe adverse effects, reduced therapeutic efficacy of co-administered drugs, or both. Clinicians must be aware of these potential interactions and adopt strategies to manage them effectively. When possible, substitute erythromycin with other antibiotics that do not inhibit CYP3A4, such as azithromycin or clarithromycin, though these may also have their own interaction profiles. Dose Adjustments, adjust the doses of co-administered drugs metabolized by CYP3A4 to maintain therapeutic levels and minimize toxicity. Increase the frequency of monitoring for therapeutic drug levels and adverse effects, particularly for drugs with a narrow therapeutic index. Inform patients about the potential for drug interactions and the importance of reporting any new medications, including over-the-counter drugs and supplements. Utilize drug interaction checkers and clinical decision support tools to identify and manage potential interactions [5,6].

Conclusion

Erythromycin is a valuable antibiotic and prokinetic agent, but its potential for drug interactions, primarily through CYP3A4 inhibition, poses significant clinical challenges. Understanding the mechanisms and clinical implications of these interactions is crucial for optimizing patient outcomes. By employing strategies such as alternative medications, dose adjustments, and vigilant monitoring, healthcare providers can mitigate the risks associated with erythromycin drug interactions and ensure safe and effective treatment.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Zheng, Yu, Yangang Chang, Sankuan Xie and Jia Song, et al. "Impacts of bioprocess engineering on product formation by Acetobacter pasteurianus." App Microbiol and Biotechnol 102 (2018): 2535-2541.

Google Scholar, Crossref, Indexed at

2. Cepec, Eva and Janja Trček. "Antimicrobial resistance of Acetobacter and Komagataeibacter species originating from vinegars." Int J Env Res and Pub Health 19 (2022): 463.

Google Scholar, Crossref, Indexed at

3. Leclercq, Roland. "Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications." Clin Infect Dis 34 (2002): 482-492.

Google Scholar, Crossref, Indexed at

4. Mahfouz, Aya A., Heba S. Said, Sherin M. Elfeky and Mona I. Shaaban. "Inhibition of erythromycin and erythromycin-induced resistance among Staphylococcus aureus clinical isolates." Antibiotics 12 (2023): 503.

Google Scholar, Crossref, Indexed at

5. Elder, Felicity CT, Edward J. Feil, JasoN Snape and William H. Gaze, et al. "The role of stereochemistry of antibiotic agents in the development of antibiotic resistance in the environment." Env Int 139 (2020): 105681.

Google Scholar, Crossref, Indexed at

6. Saichana, Natsaran, Kazunobu Matsushita, Osao Adachi and Ivo Frébort, et al. "Acetic acid bacteria: A group of bacteria with versatile biotechnological applications." Adv Biotechnol 33 (2015): 1260-1271.

Google Scholar, Crossref, Indexed at